Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Atopic Dermatitis.

Learn More

About Us
Our Science
Our Pipeline
Join Us
- Our Culture
- Job Openings
Investors & Media

Select Page

back to management

NextBio_Capital

11 of 17

11 of 17

About Us

Overview
Leadership
Collaborating
Contact

Our Science

Approach
Disease Focus
Publications & Posters

Our Pipeline

Development Pipeline
MRGPRX2 Antagonist
IL-18 Fusion Protein
Clinical Trials

Join Us

Our Culture
Job Openings

Investors & Media

Investors Overview
Company Info
News & Events
Stock Data
Financials & Filings
Governance

© 2026 Evommune, Inc.

Privacy Policy
Terms of Use

Website by 22 Fillmore